Notícias e Atividades da Janux Therapeutics

Janux Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Janux Therapeutics é uma empresa listada sob o símbolo JANX (US).

Veja o organograma con seus 28 executivos principais

Biografias mais buscadas da Janux Therapeutics

• David Campbell, Director, President and Chief Executive Officer
• Ron Barrett, Chairman of the Board
• Jake Simson, Director

Recentes movimentos de executivos em Janux Therapeutics

• Janeen Doyle, ingressou na Companhia como Chief Corporate and Business Development Officer  (Notícia publicada em 15 de maio de 2025).
• Zachariah McIver antes Vice President, Clinical Development, foi promovido a Chief Medical Officer  (Notícia publicada em 27 de janeiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Janux Therapeutics.

Janux Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Janux Therapeutics

• Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
• Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
• Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
• Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
• Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
• Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
• Janux Therapeutics Announces Proposed Public Offering
• Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
• Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
• Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
• View more press releases Close

Redes sociais sobre Janux Therapeutics

• Janux Therapeutics na Wikipedia, Google News e Yahoo Finance
• Janux Therapeutics na LinkedIn, Twitter e YouTube